{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,29]],"date-time":"2026-06-29T18:09:40Z","timestamp":1782756580062,"version":"3.54.5"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,11,25]]},"DOI":"10.7759\/cureus.74380","type":"journal-article","created":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:06:09Z","timestamp":1732525569000},"source":"Crossref","is-referenced-by-count":1,"title":["COVID-19 Pneumonia Diagnosed by Bronchoalveolar Lavage Fluid, With CD4 T-cell Depletion Contributing to Prolonged Infection: Two Case Reports"],"prefix":"10.7759","author":[{"given":"Saya","family":"Tsukida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyota","family":"Akasaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Sone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Nishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.2174\/1568009617666170109151128","article-title":"CD20-based immunotherapy of B-cell derived hematologic malignancies","volume":"17","author":"Shanehbandi D","year":"2017","unstructured":"Shanehbandi D, Majidi J, Kazemi T, Baradaran B, Aghebati-Maleki L. CD20-based immunotherapy of B-cell derived hematologic malignancies. Curr Cancer Drug Targets. 2017, 17:423-44. 10.2174\/1568009617666170109151128","journal-title":"Curr Cancer Drug Targets"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee DS","year":"2021","unstructured":"Lee DS, Rojas OL, Gommerman JL. B cell depletion therapies in autoimmune disease: advances and mechanistic insights. Nat Rev Drug Discov. 2021, 20:179-99. 10.1038\/s41573-020-00092-2","journal-title":"Nat Rev Drug Discov"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.20411\/pai.v6i1.435","article-title":"COVID-19 outcomes in patients undergoing B cell depletion therapy and those with humoral immunodeficiency states: a scoping review","volume":"6","author":"Jones JM","year":"2021","unstructured":"Jones JM, Faruqi AJ, Sullivan JK, Calabrese C, Calabrese LH. COVID-19 outcomes in patients undergoing B cell depletion therapy and those with humoral immunodeficiency states: a scoping review. Pathog Immun. 2021, 6:76-103. 10.20411\/pai.v6i1.435","journal-title":"Pathog Immun"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2021.04.010","article-title":"Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes","volume":"113","author":"Gelarden I","year":"2021","unstructured":"Gelarden I, Nguyen J, Gao J, et al.. Comprehensive evaluation of bronchoalveolar lavage from patients with severe COVID-19 and correlation with clinical outcomes. Hum Pathol. 2021, 113:92-103. 10.1016\/j.humpath.2021.04.010","journal-title":"Hum Pathol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s11739-020-02356-6","article-title":"Bronchoalveolar lavage findings in severe COVID-19 pneumonia","volume":"15","author":"Voiriot G","year":"2020","unstructured":"Voiriot G, Fajac A, Lopinto J, Labb\u00e9 V, Fartoukh M. Bronchoalveolar lavage findings in severe COVID-19 pneumonia. Intern Emerg Med. 2020, 15:1333-4. 10.1007\/s11739-020-02356-6","journal-title":"Intern Emerg Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.763412","article-title":"COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challenge","volume":"12","author":"Furlan A","year":"2021","unstructured":"Furlan A, Forner G, Cipriani L, Vian E, Rigoli R, Gherlinzoni F, Scotton P. COVID-19 in B cell-depleted patients after rituximab: a diagnostic and therapeutic challenge. Front Immunol. 2021, 12:763412. 10.3389\/fimmu.2021.763412","journal-title":"Front Immunol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2196-x","article-title":"Virological assessment of hospitalized patients with COVID-2019","volume":"581","author":"W\u00f6lfel R","year":"2020","unstructured":"W\u00f6lfel R, Corman VM, Guggemos W, et al.. Virological assessment of hospitalized patients with COVID-2019. Nature. 2020, 581:465-9. 10.1038\/s41586-020-2196-x","journal-title":"Nature"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1002\/path.5471","article-title":"Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19)","volume":"251","author":"Bourgonje AR","year":"2020","unstructured":"Bourgonje AR, Abdulle AE, Timens W, et al.. Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19). J Pathol. 2020, 251:228-48. 10.1002\/path.5471","journal-title":"J Pathol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/SHK.0000000000000633","article-title":"Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease","volume":"46","author":"Jia H","year":"2016","unstructured":"Jia H. Pulmonary angiotensin-converting enzyme 2 (ACE2) and inflammatory lung disease. Shock. 2016, 46:239-48. 10.1097\/SHK.0000000000000633","journal-title":"Shock"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005094","article-title":"Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma","volume":"5","author":"Perry C","year":"2021","unstructured":"Perry C, Luttwak E, Balaban R, et al.. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma. Blood Adv. 2021, 5:3053-61. 10.1182\/bloodadvances.2021005094","journal-title":"Blood Adv"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1111\/pai.13263","article-title":"Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover","volume":"31","author":"Soresina A","year":"2020","unstructured":"Soresina A, Moratto D, Chiarini M, et al.. Two X-linked agammaglobulinemia patients develop pneumonia as COVID-19 manifestation but recover. Pediatr Allergy Immunol. 2020, 31:565-9. 10.1111\/pai.13263","journal-title":"Pediatr Allergy Immunol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.05.013","article-title":"Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T\u00a0cell responses","volume":"40","author":"Lyudovyk O","year":"2022","unstructured":"Lyudovyk O, Kim JY, Qualls D, et al.. Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T\u00a0cell responses. Cancer Cell. 2022, 40:738-753.e5. 10.1016\/j.ccell.2022.05.013","journal-title":"Cancer Cell"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1110748","article-title":"Bendamustine associated immune suppression and infections during therapy of hematological malignancies","volume":"57","author":"Gafter-Gvili A","year":"2016","unstructured":"Gafter-Gvili A, Polliack A. Bendamustine associated immune suppression and infections during therapy of hematological malignancies. Leuk Lymphoma. 2016, 57:512-9. 10.3109\/10428194.2015.1110748","journal-title":"Leuk Lymphoma"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1026818","article-title":"Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma","volume":"56","author":"Yutaka T","year":"2015","unstructured":"Yutaka T, Ito S, Ohigashi H, Naohiro M, Shimono J, Souichi S, Teshima T. Sustained CD4 and CD8 lymphopenia after rituximab maintenance therapy following bendamustine and rituximab combination therapy for lymphoma. Leuk Lymphoma. 2015, 56:3216-8. 10.3109\/10428194.2015.1026818","journal-title":"Leuk Lymphoma"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jiac.2020.12.001","article-title":"Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient","volume":"27","author":"Nakajima Y","year":"2021","unstructured":"Nakajima Y, Ogai A, Furukawa K, et al.. Prolonged viral shedding of SARS-CoV-2 in an immunocompromised patient. J Infect Chemother. 2021, 27:387-9. 10.1016\/j.jiac.2020.12.001","journal-title":"J Infect Chemother"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-024-09631-3","article-title":"The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody","volume":"24","author":"Maruyama S","year":"2024","unstructured":"Maruyama S, Wada D, Kanayama S, et al.. The evaluation of risk factors for prolonged viral shedding during anti-SARS-CoV-2 monoclonal antibodies and long-term administration of antivirals in COVID-19 patients with B-cell lymphoma treated by anti-CD20 antibody. BMC Infect Dis. 2024, 24:715. 10.1186\/s12879-024-09631-3","journal-title":"BMC Infect Dis"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/316060-covid-19-pneumonia-diagnosed-by-bronchoalveolar-lavage-fluid-with-cd4-t-cell-depletion-contributing-to-prolonged-infection-two-case-reports","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T09:06:11Z","timestamp":1732525571000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/316060-covid-19-pneumonia-diagnosed-by-bronchoalveolar-lavage-fluid-with-cd4-t-cell-depletion-contributing-to-prolonged-infection-two-case-reports"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,25]]},"references-count":16,"URL":"https:\/\/doi.org\/10.7759\/cureus.74380","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11,25]]}}}